fbpx Skip to main content

WEDNESDAY, Oct. 21, 2020 (HealthDay News) — Vaccine-related attributes and political characteristics are associated with preference for choosing a hypothetical COVID-19 vaccine, according to a study published online Oct. 20 in JAMA Network Open.

Sarah Kreps, Ph.D., from Cornell University in Ithaca, New York, and colleagues conducted a survey study to estimate willingness to receive vaccination. A total of 1,971 respondents were presented with five choice tasks; in each, participants examined two hypothetical COVID-19 vaccines and were asked whether they would choose vaccine A, B, or neither.

The researchers found that an increase in efficacy was associated with increased probability of choosing a vaccine (50 to 70 percent: coefficient, 0.07; 50 to 90 percent: coefficient, 0.16). The probability of choosing a vaccine was increased with an increase in protection duration from one to five years (coefficient, 0.05). The probability of choosing a vaccine increased with a decrease in the incidence of major adverse effects from one in 10,000 to one in 1,000,000 (coefficient, 0.07). The probability of choosing a vaccine was lower with U.S. Food and Drug Administration emergency use authorization (coefficient, −0.03) versus full FDA approval. The probability of choosing a vaccine was lower for a vaccine that originated from a non-U.S. country (China: coefficient, −0.13; United Kingdom: coefficient, −0.04). The probability of choosing a vaccine was increased with endorsements from the U.S. Centers for Disease Control and Prevention and the World Health Organization (coefficients, 0.09 and 0.06, respectively) compared with an endorsement from President Trump.

“These results may help inform public health campaigns to address vaccine hesitancy when a COVID-19 vaccine becomes available,” the authors write.

Abstract/Full Text

You May Also Like::  COVID-19 Infection Higher Among Support Staff Than Doctors, Nurses


“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More